TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03724292

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo administered as oral capsule(s) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-43742
Description: VTP-43742 administered as oral capsule(s) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-43742
Description: VTP-43742 administered as oral capsule(s) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-43742
Description: VTP-43742 administered as oral capsule(s) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-43742
Description: VTP-43742 administered as oral capsule(s) once daily
Study: NCT00452335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 12 mcg capsule twice daily (BID)
Study: NCT03724292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-43742
Description: VTP-43742 administered as oral capsule(s) once daily
Study: NCT00452335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 mcg capsule twice daily (BID)
Study: NCT02984995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib was orally administered once daily every morning. Treatment with quizartinib was administered in 28-day cycles and continued until the discontinuation criteria for treatment were met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib was orally administered once daily every morning. Treatment with quizartinib was administered in 28-day cycles and continued until the discontinuation criteria for treatment were met.
Study: NCT04077034

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Formula Bacillus subtilis DE111®
Description: Probiotic Formula Bacillus subtilis DE111®, 1 billion colony forming units (CFU) per day for 8 weeks
Study: NCT03878056

Intervention type: DEVICE
Intervention: Vaginal: UpholdTM Lite Vaginal Support - Boston Scientific
Description: Apical prolapse reconstructive surgery by Transvaginal mesh vs Robotic sacral colpopexy

Intervention type: DEVICE
Intervention: Vaginal: UpholdTM Lite Vaginal Support - Boston Scientific
Description: Apical prolapse reconstructive surgery by Transvaginal mesh vs Robotic sacral colpopexy
Study: NCT04077034

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo comparator, once a day for 8 weeks
Study: NCT04354831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 convalescent plasma
Description: * SARS-CoV-2 convalescent plasma (1-2 units; \~200-400 mL maximum dose as 7 ml/kg adjusted IBW )~* Study drug will be administered as a single intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 convalescent plasma
Description: * SARS-CoV-2 convalescent plasma (1-2 units; \~200-400 mL maximum dose as 7 ml/kg adjusted IBW )~* Study drug will be administered as a single intravenous infusion
Study: NCT00002949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
Study: NCT03728582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS plus Speech-Language Therapy
Description: 1-2 milliamps (mA) of Anodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge is placed on the left inferior frontal gyrus (IFG). The stimulation will be delivered at an intensity of 1-2 mA in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be verb naming therapy in a sentence context.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active tDCS plus Speech-Language Therapy
Description: 1-2 milliamps (mA) of Anodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge is placed on the left inferior frontal gyrus (IFG). The stimulation will be delivered at an intensity of 1-2 mA in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be verb naming therapy in a sentence context.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS plus Speech-Language Therapy
Description: Sham tDCS stimulation is provided to the left inferior frontal gyrus (IFG) using a tDCS device. Speech-language therapy will be verb naming therapy in a sentence context.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS plus Speech-Language Therapy
Description: Sham tDCS stimulation is provided to the left inferior frontal gyrus (IFG) using a tDCS device. Speech-language therapy will be verb naming therapy in a sentence context.
Study: NCT03062488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO acetaminophen
Description: multi-modal analgesia with PO acetaminophen
Study: NCT02014402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human thrombin
Description: Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
Study: NCT01946308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conformational positioning system
Description: The conformational positioning system will be compared to the standard infant crib mattress.
Study: NCT03587259

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tomosynthesis
Description: DBT is a x-ray examination that allows to visualize the breast on 3 planes (3D) and therefore to help to see lesions hardly visible to mammography due to the overlap of glandular tissue.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 2D mammography
Description: 2D mammography is a X-ray examinations used to detect breast cancer in the screening programme.
Study: NCT04384536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neural therapy application
Description: Local injections, C5-T8 segmental injections, trigger point injections of the forearm muscles and stellate ganglion injections are applied in each session, using a 27-gauge, 4-6 cm needle. The local injection is applied first in the first extensor compartment at the point of maximal tenderness and is directed proximally toward the radial styloid.trigger point is detected, approximately 5 mL lidocaine was injected to that point. C5-T8 segmental injections are applied intradermally to each spinous process and to 0.5-2 cm lateral of each process on the affected side. Finally, the stellate ganglion injection is applied using Fischer's modified technique.
Study: NCT01034397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg (minimal dose 480mg, maximum dose 800mg) iv infusion every 4 weeks for 24 weeks
Study: NCT02014402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human thrombin
Description: Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human thrombin
Description: Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
Study: NCT00002949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2),
Study: NCT01034397

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: iv every 4 weeks for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-biological DMARDs
Description: stable dose at investigator's prescription
Study: NCT00002949

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy)
Study: NCT02204709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2N Trout
Description: Diploid/2N trout source

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3N Trout
Description: Triploid/3N trout source
Study: NCT01034397

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: non-biological DMARDs
Description: stable dose at investigator's prescription
Study: NCT00476424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days
Study: NCT02204709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tilapia
Description: Tilapia/control fish source
Study: NCT02879552

Intervention type: PROCEDURE
Intervention: Traditional upper blepharoplasty
Description: The skin incisions were marked using a skin marking pen. Preseptal orbicularis skin and muscle were removed using a size-15 scalpel blade and scissors. Hemostasis was achieved with conservative electrocuatery. The skin was closed with a running 6-0 nylon suture.

Intervention type: PROCEDURE
Intervention: Brassiere suture with blepharoplasty
Description: Prior to skin closure as above, three 6-0 polyglactin sutures are passed along the lateral fourth of the orbital rim. The sutures attach the inferior orbicularis oculi edge to the arcus marginalis of lateral ROOF. Sutures are placed until there is a visible plumping of the sub-brow tissues.
Study: NCT04259905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active video game teleconference support group
Description: 12 sessions of teleconferenced support group meetings, including active video game play + self-paced walking monitored by Fitbit wearable device

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard support group + pedometer
Description: 3 monthly sessions of in-person standard support group meetings + self-paced walking monitored by pedometer
Study: NCT02875340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL401
Description: Risperidone formulated into a liquid lipid filled capsule
Study: NCT03351894

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond laser assisted cataract surgery
Description: Ziemer Z8 femtosecond laser assisted cataract surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional phacoemulsification
Description: conventional phacoemulsification with infinity phaco
Study: NCT02014402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human thrombin
Description: Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bovine thrombin
Description: Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bovine thrombin
Description: Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
Study: NCT02102217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRECious
Description: Standardized measurement of serum CRP levels on postoperative day 3,4 and 5.
Study: NCT02014402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bovine thrombin
Description: Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bovine thrombin
Description: Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
Study: NCT04013451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acts of kindness
Description: Both intervention and control groups will receive an email with access to a relaxation and stress management booklet from Western University's (UWO) Wellness Education Centre (http://studentexperience.uwo.ca/docs/RelaxationAndStressManagement.pdf). In addition, the intervention group will be asked to (1) complete and log/submit a minimum of three deliberate acts of kindness per day for one month, and (2) join the study-dedicated online site to connect with, support, and share experiences and ideas with each other around acts of kindness.
Study: NCT02672488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Standard treatment for advanced HCC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Standard treatment for advanced HCC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: To evaluate the safety and efficacy of the combined treatment of Metformin and Sorafenib for advanced HCC
Study: NCT04138173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele coaching intervention
Description: A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
Study: NCT02204527

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplementation of 100.000 IU of vitamin D3
Description: supplementation of vitamin D ( with 2 pills of Addera D3 (50.000IU each pill))

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Description: Placebo
Study: NCT03230695

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Therapy
Description: Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Robotic Therapy
Description: Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active stimulation
Description: Active transcranial direct current stimulation will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: In sham transcranial direct current stimulation, no current will be delivered through the transcranial direct current stimulation device after the first 30 seconds.
Study: NCT00878735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zen meditation
Description: Zen meditation retreat (7 days: 5 days from 5:30 to 9:30 plus one day for adaptation and the departure day). The program starts everyday at 5:30 and finish at 9:30. In silence, the volunteers perform seating and walking meditation, stretching exercises, eating and all tasks in mindfulness.
Study: NCT03415139

Intervention type: DRUG
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: A standard OGTT will be performed. During OGTT 75gm of glucose will be given followed by phlebotomy.

Intervention type: DRUG
Intervention: 2 OGTTs with and without GLP-1 analogue
Description: A standard OGTT will be performed and a second OGTT procedure will be repeated on a different day with GLP-1 analogue.

Intervention type: DRUG
Intervention: Hyperglycemic clamp procedure
Description: During the hyperglycemic clamp procedure, D20 will given, followed by phlebotomy.
Study: NCT03991195

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplemented intervention
Description: In this project, taking the method of random, double blindness and control, the probiotic supplemented group with aMCI will take Bifidobacterium for three months. After that, cognitive changes will be test to investigate the effectiveness of probiotic supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this project, taking the method of random, double blindness and control, the placebo group with aMCI will take placebo for three months. After that, cognitive changes will be test.
Study: NCT01866436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia group
Description: Participants are provided with unrestricted access to the online multimedia educational tools for self-directed study (during the study period)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Day Group
Description: Participants in the control arm of the study attend a conventional teaching Study Day involving a series of lectures on Open and Laparoscopic Anterior Resection
Study: NCT04283734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFR pullback with Syncvision software (Volcano company)
Description: iFR pullback with Syncvision software permit us to analyze the vessel completely and to predict the physiological significance of every lesion and segment, to predict the benefit of the revascularization in terms of iFR improvement, and to predict the minimum stent length necessary to achieve this improvement.
Study: NCT04808609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumme mobile phone application
Description: Lumme mobile phone app provides smoking cessation support and tracks smoking behaviors

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care
Description: Smoking cessation counseling and nicotine replacement therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Smoking cessation counseling and nicotine replacement therapy
Study: NCT05663489

Intervention type: BEHAVIORAL
Intervention: Bergen 4-Day Treatment (B4DT)
Description: A concentrated and exposure-based psychological treatment over four consecutive days
Study: NCT02436382

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: change in temperature
Description: increase in ambient room temperature
Study: NCT01152723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: 2 mg, Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: 2 mg, Single Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: 2 mg, Single Dose
Study: NCT00970086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain/levobupivacaine
Description: Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures by the ultrasound technique, administration of 0.4ml/kg levobupivacaine 0.25%.
Study: NCT04027686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: Adjunctive application of laser therapy in the periodontal pocket

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical Scaling and Root Planing
Description: Scaling to remove calculus deposits and root planing to smooth root surfaces

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical Scaling and Root Planing
Description: Scaling to remove calculus deposits and root planing to smooth root surfaces
Study: NCT00727389

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physiotherapy
Description: Exercise two days a week for six month
Study: NCT05044741

Intervention type: PROCEDURE
Intervention: Emergency surgical enterostomy
Description: Emergency surgical enterostomy
Study: NCT02541721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LabiaStick#01
Description: This medical device has emollient agents whose main function is to increase the skin hydration, provide physical protection and decrease the symptoms and possibility of recurrence of vulvar dermatoses.~The medical device should be applied once daily, in the evening, after a gentle washing (plain water with no cleansing products), on the affected non-hairy vulvar area.
Study: NCT02205892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupeol
Description: Patients are supposed to apply 2% lupeol cream to one side of their face two times per day for 4 weeks. Application side is randomly determined.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vehicle
Description: Patients are supposed to apply their control vehicle cream two times per day to the other side of their face for 4 weeks. Application side is randomly determined.
Study: NCT00226434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early antiretroviral treatment
Description: The ARV treatment is started 2 weeks after the diagnosis and the start of the anti-tuberculosis treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late antiretroviral treatment
Description: The ARV treatment is started 8 weeks after the diagnosis and the start of the anti-tuberculosis treatment
Study: NCT00113516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC of 6 mg\*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.
Study: NCT03918980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: LOU064 will be administered as oral capsules in parts 1 to 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: LOU064 will be administered as oral capsules in parts 1 to 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: LOU064 will be administered as oral capsules in parts 1 to 6.
Study: NCT00113516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.
Study: NCT03918980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: LOU064 will be administered as oral capsules in parts 1 to 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: LOU064 will be administered as oral capsules in parts 1 to 6.
Study: NCT00113516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).
Study: NCT01782196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced one piece drainable pouch with Type A mouldable adhesive

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced one piece drainable pouch with Type A mouldable adhesive

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced one piece drainable pouch with Type B mouldable adhesive

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced one piece drainable pouch with Type B mouldable adhesive